Brain Cancer section

Brain Cancer News and Features

Targeting a unique receptor promising for glioblastoma multiforme

Glioblastoma multiforme (GBM) is one of the most lethal primary brain tumors, but new therapeutic strategies are being investigated.

Finding keys to drug therapy resistance in glioblastoma

Finding keys to drug therapy resistance in glioblastoma

Researchers have found one key as to why certain glioblastomas are resistant to drug therapy, and the answer lies in a tumor's epigenetic signature.

Repurposing antidepressant may target new medulloblastoma pathway

New research suggests that an antidepressant medication, repurposed, could target a novel molecular pathway that causes an aggressive form of medulloblastoma.

Brain mets: Time for a new approach

Brain mets: Time for a new approach

A blue-ribbon team of national experts stated that professional pessimism and out-of-date myths rather than current science may compromise the care of patients with brain cancer.

Triple therapy revs up immune system against a common brain tumor

A triple therapy for glioblastoma, consisting of two types of immunotherapy and targeted radiation, has significantly prolonged the survival of mice with these brain cancers, according to a new report.

Brain Cancer Videos

Brain Cancer Clinical Trials

PD-L1 a possible immunotherapy target in mesothelioma

Approximately one fifth of patients with malignant pleural mesothelioma have cancer cells that express a protein called programmed cell-death ligand 1 (PD-L1), which has been associated with poorer outcomes.

Improved response rate and survival with dabrafenib plus trametinib versus vemurafenib alone

Targeting BRAF V600E/K mutation-positive melanoma with dabrafenib in combination with trametinib achieves longer overall survival and impoved response rates, compared to treatment with vemurafenib alone.

Dabrafenib hitting the target in subset of patients with non-small cell lung cancer

The BRAF inhibitor dabrafenib has significant antitumor activity in patients with advanced BRAF V600E mutant non-small cell lung cancer (NSCLC) whose disease has progressed after chemotherapy, according to phase II data.

Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (ALTTO) study confirms use of trastuzumab for HER2-positive breast cancer

The use of trastuzumab (Herceptin) as the standard-of-care treatment for HER2-positive breast cancer has been supported by the Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (ALTTO) study.

Once-weekly breast radiation regimen improves on current treatment

An experimental regimen of once-weekly breast irradiation after lumpectomy provides more convenience to patients at less expense, and results in better completion rates of prescribed radiation treatment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs